Details of the Drug

General Information of Drug (ID: DMOM8AL)

Drug Name
Scopolamine
Synonyms
Atroscine; Euscopol; Hyosceine; Hysco; Isoscopil; Kwells; SEE; Scop; Scopamin; Scopolaminhydrobromid; Scopos; Sereen; Tranaxine; Transcop; Triptone; Atroscine Hydrobromide; Hydroscine hydrobromide; Hyocine F hydrobromide; Hyoscine bromide; Hyoscyine hydrobromide; SCOPOLAMINE BROMIDE; Scopolamine Hyoscine; Scopolaminium bromide; Scopolammonium bromide; Tropane alkaloid; MOLI001381; NCI61806; Borrachero (TN); Burundanga (TN); Hyoscine (TN); L-Hyoscine hydrobromide; Scopoderm-TTS; Scopolamine (INN); Transderm scop (TN); Levo-duboisine (TN); Xy-, (-)-tropate (ester); (-)-Scopolamine hydrobromide trihydrate; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epo; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epoxy-, (-)-tropate (ester); 3-Oxa-9-azatricyclo(3.3.1.O(sup 2,4))nonan-7-ol, 9-methyl-, tropate (ester); 9-methyl-3-oxa-9-azatricyclo[3.3.1.0~2,4~]non-7-yl tropate
Indication
Disease Entry ICD 11 Status REF
Addictive disorder 6C50-6C5Z Approved [1], [2]
Nausea MD90 Approved [1], [2]
Therapeutic Class
Antispasmodics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 303.35
Topological Polar Surface Area (xlogp) 0.9
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 50.8 +/- 1.76 mcgmin/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 0.54 +/- 0.1 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 23.5 +/- 8.2 min [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 13 +/- 1% [3]
Clearance
The clearance of drug is 81.2 +/- 1.55 L/h [3]
Elimination
Following oral administration, approximately 2.6% of unchanged scopolamine is recovered in urine [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 68.7 +/- 1.0 minutes (intravenous), 63.7 +/- 1.3 minutes (oral), and 69.1 +/- 8.0 minutes (intramuscular administration) [3]
Metabolism
The drug is metabolized via the liver [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.00109 micromolar/kg/day [5]
Vd
The volume of distribution (Vd) of drug is 141.3 +/- 1.6 L [6]
Water Solubility
The ability of drug to dissolve in water is measured as 666.67 mg/mL [4]
Chemical Identifiers
Formula
C17H21NO4
IUPAC Name
[(1R,2R,4S,5S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate
Canonical SMILES
CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4
InChI
InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11?,12-,13-,14+,15-,16+/m1/s1
InChIKey
STECJAGHUSJQJN-USLFZFAMSA-N
Cross-matching ID
PubChem CID
3000322
ChEBI ID
CHEBI:16794
CAS Number
114-49-8
DrugBank ID
DB00747
TTD ID
D0B7YT
VARIDT ID
DR01000

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor (CHRM) TTOXS3C NOUNIPROTAC Antagonist [7], [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Scopolamine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Bethanechol DMCLHO0 Moderate Antagonize the effect of Scopolamine when combined with Bethanechol. Abnormal micturition [MF50] [19]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Scopolamine and Oliceridine. Acute pain [MG31] [20]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Scopolamine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [21]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Scopolamine and Memantine. Alzheimer disease [8A20] [22]
Rivastigmine DMG629M Moderate Antagonize the effect of Scopolamine when combined with Rivastigmine. Alzheimer disease [8A20] [23]
Donepezil DMIYG7Z Moderate Antagonize the effect of Scopolamine when combined with Donepezil. Alzheimer disease [8A20] [23]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Scopolamine and Desipramine. Attention deficit hyperactivity disorder [6A05] [22]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Scopolamine and Loperamide. Bowel habit change [ME05] [24]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Scopolamine when combined with Acetylcholine. Cataract [9B10] [25]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Scopolamine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [26]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Scopolamine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [26]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Scopolamine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [26]
Dihydrocodeine DMB0FWL Moderate Additive CNS depression effects by the combination of Scopolamine and Dihydrocodeine. Chronic pain [MG30] [27]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Scopolamine and Olopatadine. Conjunctiva disorder [9A60] [28]
Remifentanil DMZTXCH Moderate Additive CNS depression effects by the combination of Scopolamine and Remifentanil. Corneal disease [9A76-9A78] [29]
Arbutamine DMCY8AF Moderate Increased risk of rapid heart rate by the combination of Scopolamine and Arbutamine. Coronary atherosclerosis [BA80] [30]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Scopolamine and Ethanol. Cystitis [GC00] [31]
Isocarboxazid DMAF1NB Minor Additive anticholinergic effects by the combination of Scopolamine and Isocarboxazid. Depression [6A70-6A7Z] [22]
Tranylcypromine DMGB5RE Minor Additive anticholinergic effects by the combination of Scopolamine and Tranylcypromine. Depression [6A70-6A7Z] [22]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Scopolamine and OPC-34712. Depression [6A70-6A7Z] [22]
Phenelzine DMHIDUE Minor Additive anticholinergic effects by the combination of Scopolamine and Phenelzine. Depression [6A70-6A7Z] [22]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Scopolamine and Clomipramine. Depression [6A70-6A7Z] [22]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Scopolamine and Doxepin. Depression [6A70-6A7Z] [22]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Scopolamine and Maprotiline. Depression [6A70-6A7Z] [22]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Scopolamine and Esketamine. Depression [6A70-6A7Z] [32]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Scopolamine and Mepenzolate. Digestive system disease [DE2Z] [22]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Scopolamine and Oxybutynine. Discovery agent [N.A.] [22]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Scopolamine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [33]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Scopolamine and Diphenhydramine. Episodic vestibular syndrome [AB31] [22]
Nadolol DMW6GVL Moderate Antagonize the effect of Scopolamine when combined with Nadolol. Essential hypertension [BA00] [34]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Scopolamine and Solifenacin. Functional bladder disorder [GC50] [22]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Scopolamine and Tolterodine. Functional bladder disorder [GC50] [22]
Ketoconazole DMPZI3Q Moderate Decreased absorption of Scopolamine due to altered gastric pH caused by Ketoconazole. Fungal infection [1F29-1F2F] [35]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Scopolamine and Propantheline. Gastric ulcer [DA60] [22]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Scopolamine when combined with Pilocarpine. Glaucoma [9C61] [19]
Chlorothiazide DMLHESP Minor Altered absorption of Scopolamine due to GI dynamics variation caused by Chlorothiazide. Heart failure [BD10-BD1Z] [36]
Hydroflumethiazide DMVPUQI Minor Altered absorption of Scopolamine due to GI dynamics variation caused by Hydroflumethiazide. Heart failure [BD10-BD1Z] [36]
Acebutolol DM0TI4U Moderate Antagonize the effect of Scopolamine when combined with Acebutolol. Hypertension [BA00-BA04] [34]
Penbutolol DM4ES8F Moderate Antagonize the effect of Scopolamine when combined with Penbutolol. Hypertension [BA00-BA04] [34]
Nebivolol DM7F1PA Moderate Antagonize the effect of Scopolamine when combined with Nebivolol. Hypertension [BA00-BA04] [34]
Pindolol DMD2NV7 Moderate Antagonize the effect of Scopolamine when combined with Pindolol. Hypertension [BA00-BA04] [34]
Indapamide DMGN1PW Minor Altered absorption of Scopolamine due to GI dynamics variation caused by Indapamide. Hypertension [BA00-BA04] [36]
Trichlormethiazide DMHAQCO Minor Altered absorption of Scopolamine due to GI dynamics variation caused by Trichlormethiazide. Hypertension [BA00-BA04] [36]
Hydrochlorothiazide DMUSZHD Minor Altered absorption of Scopolamine due to GI dynamics variation caused by Hydrochlorothiazide. Hypertension [BA00-BA04] [36]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Scopolamine and Belladonna. Infectious gastroenteritis/colitis [1A40] [22]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Scopolamine and Amantadine. Influenza [1E30-1E32] [37]
Propiomazine DMKY8V1 Moderate Additive anticholinergic effects by the combination of Scopolamine and Propiomazine. Insomnia [7A00-7A0Z] [22]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Scopolamine and ITI-007. Insomnia [7A00-7A0Z] [22]
R0-93877 DMM4U9G Moderate Antagonize the effect of Scopolamine when combined with R0-93877. Irritable bowel syndrome [DD91] [38]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Scopolamine and Clidinium. Irritable bowel syndrome [DD91] [22]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Scopolamine and Dicyclomine. Irritable bowel syndrome [DD91] [22]
Physostigmine DM2N0TO Moderate Antagonize the effect of Scopolamine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [25]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Scopolamine and Lasmiditan. Migraine [8A80] [39]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Scopolamine and Flibanserin. Mood disorder [6A60-6E23] [40]
Neostigmine DM6T2J3 Moderate Antagonize the effect of Scopolamine when combined with Neostigmine. Myasthenia gravis [8C6Y] [41]
Edrophonium DMCRQHB Moderate Antagonize the effect of Scopolamine when combined with Edrophonium. Myasthenia gravis [8C6Y] [41]
Ambenonium DMOP0BL Moderate Antagonize the effect of Scopolamine when combined with Ambenonium. Myasthenia gravis [8C6Y] [41]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Scopolamine and Phenindamine. Nasopharyngitis [CA00] [22]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Scopolamine and Promethazine. Nausea/vomiting [MD90] [22]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Scopolamine and Cyclizine. Nausea/vomiting [MD90] [22]
Metoclopramide DMFA5MY Moderate Antagonize the effect of Scopolamine when combined with Metoclopramide. Nausea/vomiting [MD90] [42]
Polythiazide DMCH80F Minor Altered absorption of Scopolamine due to GI dynamics variation caused by Polythiazide. Oedema [MG29] [36]
Levomethadyl Acetate DM06HG5 Moderate Additive CNS depression effects by the combination of Scopolamine and Levomethadyl Acetate. Opioid use disorder [6C43] [27]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Scopolamine and Apraclonidine. Optic nerve disorder [9C40] [43]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Scopolamine and Oxymorphone. Pain [MG30-MG3Z] [20]
Levorphanol DMGS80V Moderate Additive CNS depression effects by the combination of Scopolamine and Levorphanol. Pain [MG30-MG3Z] [20]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Scopolamine and Dezocine. Pain [MG30-MG3Z] [20]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Scopolamine and Flavoxate. Pain [MG30-MG3Z] [22]
Nalbuphine DMOSQGU Moderate Additive CNS depression effects by the combination of Scopolamine and Nalbuphine. Pain [MG30-MG3Z] [20]
Buprenorphine DMPRI8G Moderate Additive antimotility effects by the combination of Scopolamine and Buprenorphine. Pain [MG30-MG3Z] [20]
Hydrocodone DMQ2JO5 Moderate Additive CNS depression effects by the combination of Scopolamine and Hydrocodone. Pain [MG30-MG3Z] [29]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Scopolamine and Biperiden. Parkinsonism [8A00] [22]
Levodopa DMN3E57 Moderate Altered absorption of Scopolamine due to GI dynamics variation caused by Levodopa. Parkinsonism [8A00] [44]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Scopolamine and Orphenadrine. Parkinsonism [8A00] [22]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Scopolamine and Methylscopolamine. Peptic ulcer [DA61] [22]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Scopolamine and Levomepromazine. Psychotic disorder [6A20-6A25] [22]
Quetiapine DM1N62C Moderate Additive anticholinergic effects by the combination of Scopolamine and Quetiapine. Schizophrenia [6A20] [22]
Mesoridazine DM2ZGAN Moderate Additive anticholinergic effects by the combination of Scopolamine and Mesoridazine. Schizophrenia [6A20] [22]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Scopolamine and Aripiprazole. Schizophrenia [6A20] [22]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Scopolamine and Iloperidone. Schizophrenia [6A20] [22]
Paliperidone DM7NPJS Moderate Additive anticholinergic effects by the combination of Scopolamine and Paliperidone. Schizophrenia [6A20] [22]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Scopolamine and Perphenazine. Schizophrenia [6A20] [22]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Scopolamine and Molindone. Schizophrenia [6A20] [22]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Scopolamine and Thiothixene. Schizophrenia [6A20] [22]
Trifluoperazine DMKBYWI Moderate Additive anticholinergic effects by the combination of Scopolamine and Trifluoperazine. Schizophrenia [6A20] [22]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Scopolamine and Asenapine. Schizophrenia [6A20] [22]
Pimozide DMW83TP Moderate Additive anticholinergic effects by the combination of Scopolamine and Pimozide. Schizophrenia [6A20] [22]
Fentanyl DM8WAHT Moderate Additive antimotility effects by the combination of Scopolamine and Fentanyl. Sensation disturbance [MB40] [20]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Scopolamine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [22]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Scopolamine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [22]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Scopolamine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [21]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Scopolamine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [22]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Scopolamine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [22]
⏷ Show the Full List of 93 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 330).
2 Drug Information of Calcidiol from nextbio research in illumina. 2015.
3 Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Ther Drug Monit. 2005 Oct;27(5):655-65. doi: 10.1097/01.ftd.0000168293.48226.57.
4 BDDCS applied to over 900 drugs
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 FDA Approved Drug Products: TRANSDERM SCOP (scopolamine) patch
7 The amygdala modulates morphine-induced state-dependent memory retrieval via muscarinic acetylcholine receptors. Neuroscience. 2009 May 5;160(2):255-63.
8 Midbrain acetylcholine and glutamate receptors modulate accumbal dopamine release. Neuroreport. 2008 Jun 11;19(9):991-5.
9 Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol. 2004 Jan;65(1):257-66.
10 Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013 May;345(2):260-70.
11 Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors. J Recept Signal Transduct Res. 1997 Jan-May;17(1-3):177-84.
12 Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J Pharmacol Exp Ther. 2002 Oct;303(1):29-35.
13 Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line. J Pharmacol Exp Ther. 1998 Feb;284(2):500-7.
14 Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in conscious dogs. Nihon Yakurigaku Zasshi. 1999 Mar;113(3):157-66.
15 Clinical pipeline report, company report or official report of GlaxoSmithKline.
16 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
17 Competitive and non-competitive antagonism exhibited by 'selective' antagonists at atrial and ileal muscarinic receptor subtypes. Br J Pharmacol. 1987 Apr;90(4):701-7.
18 Long-acting bronchodilators in COPD: Where are we now and where are we going Breathe 06/2014; 10(2):110-120.
19 Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
20 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
21 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
22 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
23 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
24 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
25 Multum Information Services, Inc. Expert Review Panel.
26 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
27 Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
28 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
29 Product Information. Levorphanol Tartrate (levorphanol). Sentynl Therapeutics, Solana Beach, CA.
30 Product Information. GenESA (arbutamine). Gensia Inc, San Diego, CA.
31 Linnoila M "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol 6 (1973): 107-12. [PMID: 4588850]
32 Cerner Multum, Inc. "Australian Product Information.".
33 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
34 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
35 Product Information. Nizoral (ketoconazole). Janssen Pharmaceutica, Titusville, NJ.
36 Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798]
37 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
38 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
39 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
40 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
41 Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
42 Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON.
43 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
44 Algeri S, Cerletti C, Curcio M, et al. "Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and man." Eur J Pharmacol 35 (1976): 293-9. [PMID: 1248506]